The Japan Society of Clinical Pathology (JSCP) 5 has developed practice guidelines for efficacious test utilization to compete against the rapid expansion of diagnostic test usage in the past two decades in Japan. The JSCP subcommittee has established a panel test system to be applied to every new outpatient in primary care medicine, designating the test packages as the "Essential Laboratory Tests (ELT)" panels. The ELT panels, according to the JSCP, should be performed at the initial clinical evaluation of new outpatients regardless of the clinic or patient's disease categories in parallel with a history and physical examination (1 ) . The ELT panels are composed of two panels, ELT(1) and ELT (2) , the compositions of which are shown in Table 1 ; the JSCP intends for the ELT(1) basic panel to be universally ordered at the first evaluation of new primary care outpatients as routine testing to obtain minimally essential information for a disease or patient's physical condition, whereas the ELT(2) panel tests, including optional chest and abdominal plain x-rays and electrocardiogram (ECG), should be performed selectively to focus the initial clinical diagnosis if necessary.
In our previous study (2 ) , we analyzed the costeffectiveness of the ELT panels for providing information that contributed to a change in a physician's tentative initial diagnosis (TID) or in a physician's decision-making in new outpatients with symptoms. The utility of the ELT panels varied widely among patient groups, with the highest yield (in patients with hematologic disease) 20-fold higher than the lowest yield (in patients with neurologic disease) (2 ) . Despite the JSCP's recommendation, we concluded that selective test combinations should be used for selected patient groups. In that study, however, we did not assess an additional potential advantage of a panel test system, i.e., its utility for identification of occult disease. Although the JSCP guideline stated that the panel test system should be directed to new primary care outpatients with defined symptoms for the purpose of clinical evaluation of a patient's illness, the ELT can uncover unforeseen, additional disease(s) unrelated to a patient's chief complaint. Therefore, the enforcement of the ELT panel testing also provides an opportunistic screening for some occult diseases among a symptomatic patient population.
In the current move to avoid unnecessary testing in the United States and other countries, panel testing is discouraged and efforts are made to use more carefully selected individual tests or small groups of tests. Screening-test profiles without distinct cost-effectiveness have not been generally accepted (3) (4) (5) . Certainly, there may be a consensus that screening-test profiles for occult disease detection should not be applied to healthy populations without symptoms or risk factors for a disease (5, 6 ) . Furthermore, screening tests may have potentially harmful effects from false-positive or -negative results (7 ). However, identification and early management of silent but significant diseases such as dyslipidemia and diabetes, which frequently require high-cost medical care at the symptomatic stage, may ultimately be cost-effective: early discovery of a disease can lead to its arrest, reversal, or cure, and thereby decrease morbidity and mortality (8 ) , reducing overall costs for total medical care. Although one of the current principal tenets of the third-party payers of health insurance is to eliminate unnecessary testing, elimination of some tests may increase the total cost of medical care. The Medicare billing regulations that became effective in April 1998 allow small panels such as lipid profiles based on automated multichannel analyzers (9 ) . Nevertheless, there are very few studies that accurately analyze cost-effectiveness for opportunistic screening of asymptomatic, occult diseases.
In the present study, we evaluated the clinical and economic efficiency 6 of the ELT panels for opportunistic finding of occult disease in symptomatic patients. We discuss this utility of the JSCP panel test system separately from its validity for clinical evaluation of manifested diseases.
Patients and Methods patients
Among all new outpatients who visited the Comprehensive Medicine Clinics, National Defense Medical College, Tokorozawa, Japan and its affiliated hospital from June 1991 to March 1997, 540 patients (250 males, 290 females; age range, 9 -83 years) who had defined symptoms and who were seen by physicians certified by the Japanese Boards of Internal Medicine and Clinical Pathology were entered in this study. Patients were eligible irrespective of their symptoms or disease categories, without any selection process except for those referred by physicians in other medical facilities with test results and/or tentative clinical diagnoses. These patients were excluded in advance from the study or not evaluated in the analyses. Patients were universally given a diagnostic test package corresponding to the ELT(2) ( Table 1 ) with the addition of serum cholinesterase after a history and physical examination. Diagnostic sensitivity, specificity, and positive predictive values of the individual panel components were analyzed in our preliminary study and described elsewhere (10 ) . Chest and abdominal plain x-rays, ECGs, fecal occult blood tests, and serological tests for hepatitisrelated virus antigen or antibody and syphilis were optional choices. Diagnoses were divided into the TID, which was tentatively made by the primary care physician from the history and physical examination alone, and the "initial clinical diagnosis" which was established after integrating the results of diagnostic tests. A diagnosis related to a patient's chief complaint was defined as the "primary diagnosis or disease", whereas those uncovered by abnormal test results that were unexpectedly elicited by the enforcement of the ELT and not related directly to a patient's illness were defined as "additional diagnoses or occult diseases". An "occult disease" indicates a silent but clinically significant disease, whereas a patient's asymptomatic abnormal health condition, which has subclinical or uncertain significance but influences a physician's decision-making, is designated as an "occult abnormal health status" uncovered by the test results.
assay methods and diagnostic criteria for occult diseases
Assay methods for the common diagnostic tests performed have been described in detail elsewhere (2 ) . Briefly, chemistry tests, complete blood count and leukocyte differential count, C-reactive protein (CRP), sialic acid, and serum protein profiles (protein fractions) were analyzed on automated multichannel analyzers. Because sialic acid is considered a delayed responder to inflammation and to show a different movement in the inflammation process from CRP, this test is also adopted in the ELT(2) panel. Dipstick urinalysis was performed manually. The standard Westergren method was used for the measurement of erythrocyte sedimentation rate. Chest and abdominal plain x-rays, an ECG, and a fecal occult blood test were optionally ordered if necessary. Microscopic examination of a peripheral blood smear was performed in samples with any abnormality in complete blood count or qualitative abnormalities detected by the analyzer. Diagnoses were established according to the reference values that were adopted in the hospitals in which this study was carried out, with the exception of hypercholesterolemia. Although the total cholesterol concentration is 3.50 -5.96 mmol/L (135-230 mg/dL) in 95% of healthy individuals in Japan, its "normal" upper limit is placed at 5.70 mmol/L (220 mg/dL) in many hospitals in this country according to the clinical guideline issued by the Japan Atherosclerosis Society, which emphasizes on the lower value of cholesterol from the standpoint of disease prevention. Suspected diagnosis for diabetes mellitus was made by a positive glucose in dipstick urinalysis in combination with Ͼ7.77 mmol/L (140 mg/dL) in a random serum glucose value. A renal/urinary tract disease was suspected by two or more strongly positive reactions in urinalysis (at least protein and occult blood) or obvious abnormalities in a patient's urine sediment with or without increased serum creatinine or urea nitrogen.
clinical efficiency, costs, and cost-effectiveness
Because of a lack of availability of cost data at the National Defense Medical College Hospital, costs 7 were calculated by considering all expenditures required to obtain test results at the Kawasaki Medical School Hospital (Kurashiki, Japan), which is a tertiary hospital similar to the National Defense Medical College Hospital with respect to size, geographic location, and surrounding population distribution. Costs included costs for test reagents and analyzer operation, equipment amortization, and personnel expenses for medical technologists. Indirect costs were excluded.
The clinical efficiency of the ELT is expressed as the number of additional, occult diseases per patient in each disease category. The economic efficiency of the ELT is defined as the cost required per occult disease detected, and cost-effectiveness was determined as incremental cost for tests added to the ELT(1) baseline panel per an incremental occult disease uncovered by the added tests (⌬cost/⌬occult disease).
reconstructed panels and simulated costeffectiveness of new panels
The test package performed for 540 new outpatients included all components of the ELT(1) panel. We modified the cumulated database to contain patients' chief complaints, TIDs, and test results of the ELT(1) items alone but not to include initial clinical diagnoses obtained from interpretation of all test items actually performed, and then reestablished the initial diagnosis with results of the ELT(1) components alone, simultaneously assigning additional, occult diseases based on the ELT(1) in individual patients. The results were compared with those obtained from test components corresponding to the ELT(2). We further extended the study to pursue a test combination that can provide the maximal clinical efficiency at a minimal cost increment, analyzing occult diseases detected and costs required after certain ELT(2)-specific test components were added to the ELT(1) basic panel.
If patients were asymptomatic and had no abnormal findings on physical examination, additional diagnoses for diseases such as hyperlipidemia, liver dysfunction, hyperuricemia, or diabetes mellitus could not be established by the ELT(1) alone because of limited test items for diagnostic evaluation of these diseases.
Results
clinical and economic efficiency of the elt panels for occult disease finding History and physical examination alone generated 633 effective TIDs among 540 patients (2 ) . Application of the ELT(2) produced 692 primary initial clinical diagnoses corresponding to patients' illness and 276 additional diagnoses of occult disease or abnormal health status, the latter being uncovered as a result of the disease screening effect of the panel. As shown in Table 2 , the most frequent additional, occult disease was hyperlipidemia (n ϭ 100), followed by liver dysfunction (n ϭ 53), hematological disease or abnormality (n ϭ 33), and suspected renal/ urinary tract disease (n ϭ 33 cases).
The clinical efficiency of the ELT(2) extensive panel was 0.51 occult disease/patient at a cost of ¥4104/occult disease for the overall patient population (Table 3) and varied depending on the TID category. The clinical efficiency of the ELT(2) was 1.1-0.40 occult disease/patient, and the cost required per occult disease detected was ¥1968 -5524/occult disease. Renal/urinary tract disease, cardiovascular disease, and respiratory disease groups demonstrated higher clinical and economic efficiency (1.1, 0.94, and 0.88 occult disease/patient at costs of ¥1968, ¥2879, and ¥3141/occult disease, respectively). The ELT(1) baseline panel, which should be applied to every new patient, uncovered only 79 cases with occult diseases or abnormal health status. Compared with the ELT(2), there were remarkable decreases in clinical and economic efficiency with the ELT(1): 0.15 occult disease/patient at a cost of ¥6289/occult disease for the overall patient population. The best cost-effectiveness (⌬cost/⌬occult disease) of the ELT(2) for occult disease detection was for the renal/urinary tract disease group (¥1521) followed by the neurological disease (¥2251) and respiratory disease (¥2402 per incremental occult disease) groups, although the case numbers were small in these three disease categories. The cost-effectiveness of the ELT(2) was ¥3228 per incremental occult disease for the overall patient population.
panel components contributing to occult disease finding
The frequencies of test items contributing to the detection of additional, occult diseases are shown in Fig. 1 . In total, 511 tests detected 276 cases of occult disease or silent abnormal health status. Basic diagnostic tests constituting the ELT(1) made up only 22% of the total tests contributing to occult disease detection. This low frequency corresponded to the poor clinical and economic efficiency of the ELT(1) for occult disease finding (Table 3) . Reflecting the prevalence of the occult diseases in our patient population (Table 2) , total cholesterol was the test that most frequently contributed to the detection of an occult disease (hyperlipidemia), followed by alanine aminotransferase (ALT) for liver dysfunction and cholinesterase for possible fatty liver in patients with increased liver transaminases. At the initial clinical evaluation, it was difficult to diagnose hyperlipidemia with the triglyceride value alone because of its large fluctuations related to postprandial status. The frequencies of chest x-rays and ECGs contributing to the detection of unforeseen, significant diseases were very low, despite the higher costs for both tests (¥877 and ¥699 per test, respectively).
simulated cost-effectiveness of reconstructed test panels
Considering the individual test items that largely contributed to the discovery of additional, silent diseases, we redesigned new panels based on the ELT(1), the most fundamental test package, adding some ELT(2) test items, and then analyzed the cost-effectiveness of the new panels to seek more efficient test combinations for occult disease finding. As shown in Table 4 , the addition of only four automated analyzer-based chemistry tests (total cholesterol, ALT, glucose, and uric acid) to the ELT(1) test components produced remarkably improved clinical and economic efficiency (0.41 occult disease/patient and ¥2372/occult disease, respectively) at a cost-effectiveness of ¥177 per incremental occult disease (Table 4 , panel A).
Addition of more of the ELT(2) test items to the ELT (1) slightly increased clinical efficiency but decreased costeffectiveness (Table 4 , panels B and C). Optional test items (chest and abdominal x-rays, ECG, and fecal occult blood test) scarcely contributed to the improvement in clinical efficiency, but rather increasingly worsened cost-effectiveness for occult disease finding [compare cost-effectiveness of panel C with that of the ELT(2) in Table 4 ].
Discussion
The present study is a counterpart of our previous study, which analyzed cost-effectiveness of the ELT panels for clinical evaluation of patients' presenting illness (2 ). In our earlier study, however, we did not refer to the case-finding efficiency of the panels. Although biochemical profile testing for the purpose of case-finding among asymptomatic adults is not currently recommended in general (11 ) , it seems to be acceptable to apply some selective tests, which can uncover clinically silent but significant diseases such as hypercholesterolemia and diabetes, to certain patients who appear to have risks for coronary heart disease or stroke. There is a higher prevalence of hepatitis virus-induced chronic liver dis- Fig. 1 . The ELT components and their frequency of contribution to occult disease finding.
Filled columns indicate contributions of the ELT(1) component tests to occult disease finding; hatched columns indicate those of the ELT(2)-specific test items. In total, 511 tests contributed to discovery of 276 additional, occult diseases among 540 new outpatients. WBC, white blood cell count; A/G ratio, albumin/globulin ratio; RBC indices, red blood cell indices; ESR, erythrocyte sedimentation rate; GGT, ␥-glutamyltransferase; AST, aspartate aminotransferase; LD, lactate dehydrogenase; ALP, alkaline phosphatase; LDC, leukocyte differential count; BUN, serum urea nitrogen. ‫ء‬ indicates optionally ordered tests.
eases and subsequent hepatocellular carcinoma in Japan than in Western countries, prompting the need to find asymptomatic patients with liver dysfunction (12 ) . Recent advances in medical technology allow inexpensive testing of total cholesterol, serum glucose, and other automated multichannel analyzer-based chemistry tests. The issue is not the expense of testing itself, but what is required is persuasive, strong evidence based on cost-effectiveness evaluations for the validity of a screening program.
As shown in Table 3 , there is a substantial disparity in the cost-effectiveness of the ELT panels for additional, occult disease detection. A higher prevalence of occult diseases and the favorable cost-effectiveness indicators of the ELT(2) panel were demonstrated in cardiovascular, renal/urinary tract, and respiratory disease groups, although the small numbers of patients do not allow a conclusive statement in the latter two disease categories. Except for these three disease groups, clinical efficiency and economic consequence of the ELT(2) were poor among our patients. This corresponds to experts' opinion that the performance of a general battery of biochemical tests is not recommended for screening of asymptomatic adults (11 ) . Patients with cardiovascular TIDs seem to be the only group for whom the extensive test panels, rather than the basic one [the ELT(1)], are indicated for occult disease detection on the basis of cost-effectiveness, and active efforts to screen for diseases such as hypercholesterolemia and diabetes, which are known risk factors for atherosclerosis, should at least be directed toward this patient group. In the case of cholesterol screening, clinical guidelines issued by the National Cholesterol Education Program (13 ) and by the American College of Physicians (14, 15 ) state that all adults older than 20 years (the former) or primarily middle-aged men (the latter) with hypercholesterolemia be identified, educated, and treated. In addition, recent clinical trials showed that cholesterol reduction confers survival benefits in patients with symptomatic coronary heart disease ( 16 -18 ) and lowers the incidence of cardiovascular morbidity and mortality in patients without coronary symptoms (19, 20 ) . Cholesterol reduction decreases the incidence of stroke as well (21 ) . Likewise, the CDC Diabetes Cost-Effectiveness Study Group recently demonstrated that early diagnosis and treatment of type 2, non-insulin-dependent diabetes through opportunistic screening may reduce the lifetime incidence of major microvascular complications, producing gains in both life-years and quality-adjusted life-years with an acceptable cost-effectiveness for the US healthcare system (22 ) . These recommendations and results obtained from the clinical trials might support physicians' efforts for screening of significant occult diseases for which patient education, management, and early treatment are effective in preventing disease progression, ultimately providing cost-effective medical care. The validity of proposed screening programs should be endorsed by a broad range of cost-effectiveness analyses.
Comparison of the ELT(1) with the ELT(2) demonstrated limited utility of the former baseline panel in the aspect of clinical and economic efficiency for occult disease finding in all disease categories (0.15 occult disease/ patient at a cost of ¥6289/occult disease). Although application of the entire ELT(2) panel to patients considerably improved the overall clinical efficiency (up to 0.51 in occult disease/patient tested), cost remained high [¥4104 (ϳ$40 US)/occult disease; Table 3 ]. The poor cost-effectiveness (⌬cost/⌬occult disease) of the ELT(2) vs the ELT(1) baseline panel prompted us to seek more efficient test combinations, adding one or more ELT(2)-specific test items that highly contributed to occult disease detection to the ELT(1) panel. As anticipated from Fig. 1 , the cost-effectiveness indicators were markedly improved by the addition of only four automated analyzer-based chemistry tests (total cholesterol, ALT, glucose, and uric acid) at an excellent cost-effectiveness of ¥177 per incremental occult disease (Table 4 , panel A). Addition of more of the ELT(2) test components to this redesigned panel minimally increased clinical efficiency and decreased cost-effectiveness. In particular, plain x-rays and ECGs showed little utility for the discovery of occult diseases in our patients because of an extremely low prevalence of clinically silent but significant organic diseases and higher costs for performing these tests. This finding entirely supports the recommendations from the Medical Necessity Project of the American College of Physicians for common diagnostic test utilization, which indicate a limited usefulness of chest x-rays and ECGs as routine screening diagnostic procedures even for a baseline evaluation of preoperative patients or at the time of hospital admission (7, 23 ) . Our previous studies recommended the utilization of selective ELT panels for selected patient groups such as those with liver/pancreatobiliary, metabolic/endocrine, or cardiovascular diseases (2 ), or those with infection/ inflammation-related, renal/urinary tract, or lassitude/ exhaustive symptoms (24 ) . In addition to the utility of the ELT for the clinical evaluation of the illness of which a patient complains, silent diseases can be simultaneously screened with the use of this panel test system. Indeed, our present study demonstrated that the addition of total cholesterol, ALT, and random serum glucose to the ELT(1) enabled the detection of 100, 53, and 13 cases of hypercholesterolemia, liver dysfunction, and suspected diabetes mellitus, respectively, among 540 new outpatients in our institutes with acceptable cost-effectiveness. Incorporating these results with our previous studies relating to the cost-effectiveness of the ELT panels, clinical evaluation of a patient's illness by the selective use of this panel system could be accompanied by opportunistic screening of significant occult diseases. Thus, each selective panel for selected patients could include the ELT(2)-specific chemistry test items that largely contribute to the discovery of the clinically silent but significant diseases shown above.
In conclusion, although the JSCP panel test system has supplemental utility for the opportunistic screening of some significant, occult diseases, universal utilization of the full panel [the ELT(2)] is not supported by the cost-effectiveness found in our studies. Simultaneous screening of specific occult disease(s), however, might be valid and further improve the clinical and economic efficiency of the panel test system when the panels are given to selected patients for clinical evaluation of their illnesses. Our cost-effectiveness analysis demonstrated specific screening test items that could be added to each selective panel for certain patient groups. The validity of enforcing such screening tests alone to all or only risky individuals is uncertain in our current studies.
